Ieq Capital LLC Buys 2,146 Shares of Kenvue Inc. (NYSE:KVUE)

Ieq Capital LLC increased its stake in shares of Kenvue Inc. (NYSE:KVUE) by 20.0% during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 12,853 shares of the company’s stock after acquiring an additional 2,146 shares during the period. Ieq Capital LLC’s holdings in Kenvue were worth $274,000 as of its most recent filing with the SEC.

Several other large investors have also recently bought and sold shares of KVUE. Huntington National Bank raised its stake in shares of Kenvue by 26.5% during the 3rd quarter. Huntington National Bank now owns 4,161 shares of the company’s stock worth $96,000 after purchasing an additional 871 shares in the last quarter. ING Groep NV raised its position in Kenvue by 23.6% during the third quarter. ING Groep NV now owns 3,576,616 shares of the company’s stock worth $82,727,000 after acquiring an additional 681,954 shares in the last quarter. Alberta Investment Management Corp lifted its stake in Kenvue by 23.2% in the fourth quarter. Alberta Investment Management Corp now owns 582,895 shares of the company’s stock valued at $12,445,000 after acquiring an additional 109,700 shares during the last quarter. Empower Advisory Group LLC bought a new position in shares of Kenvue in the 4th quarter valued at about $48,252,000. Finally, Golden State Equity Partners increased its stake in shares of Kenvue by 716.1% during the 4th quarter. Golden State Equity Partners now owns 25,658 shares of the company’s stock worth $548,000 after purchasing an additional 22,514 shares during the last quarter. 97.64% of the stock is owned by institutional investors and hedge funds.

Kenvue Price Performance

KVUE stock opened at $23.58 on Friday. The company’s 50-day moving average price is $21.46 and its two-hundred day moving average price is $22.26. Kenvue Inc. has a 12 month low of $17.67 and a 12 month high of $24.46. The company has a quick ratio of 0.69, a current ratio of 1.00 and a debt-to-equity ratio of 0.66. The firm has a market cap of $45.07 billion, a P/E ratio of 44.49, a P/E/G ratio of 2.62 and a beta of 1.45.

Kenvue (NYSE:KVUE) last announced its quarterly earnings data on Thursday, February 6th. The company reported $0.26 EPS for the quarter, meeting the consensus estimate of $0.26. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. On average, analysts anticipate that Kenvue Inc. will post 1.14 earnings per share for the current fiscal year.

Kenvue Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, February 26th. Investors of record on Wednesday, February 12th were paid a $0.205 dividend. This represents a $0.82 annualized dividend and a yield of 3.48%. The ex-dividend date of this dividend was Wednesday, February 12th. Kenvue’s dividend payout ratio (DPR) is presently 154.72%.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on KVUE. Deutsche Bank Aktiengesellschaft downgraded shares of Kenvue from a “buy” rating to a “hold” rating and cut their target price for the company from $25.00 to $24.00 in a research note on Thursday, December 12th. Citigroup reduced their target price on Kenvue from $25.00 to $21.00 and set a “neutral” rating for the company in a research note on Wednesday, January 15th. Royal Bank of Canada restated a “sector perform” rating and issued a $24.00 price target on shares of Kenvue in a research note on Monday, February 3rd. Barclays reduced their price objective on shares of Kenvue from $23.00 to $21.00 and set an “equal weight” rating for the company in a research report on Friday, January 17th. Finally, Piper Sandler upped their price objective on shares of Kenvue from $24.00 to $27.00 and gave the company an “overweight” rating in a report on Monday, February 24th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $23.08.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.